Kurzfassung

A randomized phase II multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of Onartuzumab (MetMab) in combination with either Bevacizumab+Platinum+Placlitaxel or Pemetrexed+Platinum as first-line treatment in patients with stage III B or IV non-squamous, non-small cell lung cancer (NSCLC)